Helen Jeon

Helen Jeon

Auto-generated profile, based on publicly available information

Helen Jeon

Division of Plastic and Reconstructive Surgery, Rush University Medical Center, Chicago, IL

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2026 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
EGEmmanuel Giannas
Emmanuel Giannas
AFAnnie M. Fritsch
Annie M. Fritsch
HJHelen Jeon
Helen Jeon
ZVZachary Valenzuela
Zachary Valenzuela
IIIme D. Inyang
Ime D. Inyang
GKGeorge Kokosis
George Kokosis

7 March 2026 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
HJHelen Jeon
Helen Jeon
AYAnna Yum
Anna Yum
IPIdanis Perez-Alvarez
Idanis Perez-Alvarez
DNDarren Nin
Darren Nin
CKChristodoulos Kaoutzanis
Christodoulos Kaoutzanis
GKGeorge Kokosis
George Kokosis

20 May 2026 in Aesthetic Surgery Journal
Verified
Journal Article
Closed access
NRNikki Rezania
Nikki Rezania
KHKelly A Harmon
Kelly A Harmon
OLOkensama La-Anyane
Okensama La-Anyane
AFAnnie Fritsch
Annie Fritsch
HJHelen Jeon
Helen Jeon
GKGeorge Kokosis
George Kokosis
Background: The SPY Fluorescence Imaging system enables intraoperative visualization of microvascular perfusion. Recently, SPY has been integrated with Quantitative Perfusion (QP) software to provide numerical assessment of relative tissue perfusion; however, clinically actionable perfusion thresholds predictive of mastectomy skin necrosis complications have not been clearly established. Objectives: The aim of this study was to evaluate the predictive performance of proposed SPY Portable Handheld Imaging Quantitative Perfusion (PHI QP) perfusion thresholds in patients undergoing staged breast reconstruction and to explore a QP-specific cutoff while accounting for nitroglycerin ointment use as a potential confounder. Methods: Patients undergoing staged breast reconstruction with tissue expander placement were included. SPY-PHI QP was used intraoperatively to assess relative perfusion. Diagnostic performance metrics—including sensitivity, specificity, positive predictive value, negative predictive value, accuracy, and odds ratios—were calculated. A subanalysis excluding patients who received nitroglycerin ointment was performed to identify a QP-specific cutoff in unmanipulated tissue. Results: Fifty-eight patients (83 breasts) were included. Using a 33% perfusion threshold, SPY-PHI QP demonstrated high sensitivity (87.5%) and negative predictive value (98.3%) for mastectomy skin flap necrosis. After adjusting for nitroglycerin use, the association between low perfusion and mastectomy skin flap necrosis was attenuated. In patients who did not receive nitroglycerin, a perfusion threshold of 30% demonstrated optimal diagnostic performance (sensitivity 100%, specificity 76.7%, area under the curve 0.8875). Conclusions: SPY-PHI QP provides quantitative, real-time assessment of tissue perfusion during breast reconstruction. In patients not treated with nitroglycerin, a 30% perfusion threshold may be predictive of wound complications. These findings support further investigation of QP-specific thresholds in larger, prospective studies that account for adjunctive interventions. Level of Evidence: 4 (Therapeutic): For image description, please refer to the figure legend and surrounding text.